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Improved access to healthcare, vaccines and treatment with antibiotics has reduced global mortality from childhood
community-acquired pneumonia. However, as respiratory viruses are responsible for most episodes of pneumonia,
important questions remain over who should receive these agents and the length of each treatment course. Worldwide
concerns with increasing antibiotic resistance in respiratory pathogens and appeals for more prudent antibiotic
prescribing provide further urgency to these clinical questions. Unfortunately, guidelines for treatment duration in
particular are based upon limited (and often weak) evidence, resulting in national and international guidelines
recommending treatment courses for uncomplicated pneumonia ranging from 3 to 10 days. The advantages of short-
course therapy include a lower risk of developing antibiotic resistance, improved adherence, fewer adverse drug effects,
and reduced costs. The risks include treatment failure, leading to increased short- or long-term morbidity, or even
death. The initial challenge is how to distinguish between bacterial and non-bacterial causes of pneumonia and then to
undertake adequately powered randomised-controlled trials of varying antibiotic treatment durations in children who
are most likely to have bacterial pneumonia. Meanwhile, healthcare workers should recognise the limitations of current
pneumonia treatment guidelines and remember that antibiotic course duration is also determined by the child’s
response to therapy.
Keywords: Pneumonia, Antibiotics, ChildCommunity-acquired pneumonia is the leading global
cause of childhood morbidity and mortality. Annually,
there are an estimated 120–160 million clinical pneumonia
episodes worldwide, causing 14 million hospitalisations
and almost one million deaths in children aged <5 years
[1, 2]. Although respiratory viruses are the most common
pathogens associated with childhood pneumonia, most
deaths are attributed to Streptococcus pneumoniae and
Haemophilus influenzae type b [3]. Consequently, antibi-
otics have reduced pneumonia-related morbidity and mor-
tality. Nevertheless, several knowledge gaps exist with
prescribing antibiotics for pneumonia, including the opti-
mal length of treatment required. These limitations are
evident in both national and international guidelines,
which have had to rely upon expert opinion and weak
levels of evidence from a small number of clinical trials
with substantial methodological limitations [4–7]. A good* Correspondence: k.grimwood@griffith.edu.au
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tions provided on treatment duration for uncomplicated
childhood pneumonia [5, 6]. This raises several questions
for healthcare workers when determining how long they
should be giving antibiotics to a child with pneumonia.What factors influence decisions on antibiotic
duration?
Several factors are considered when both choosing an
antibiotic to treat a suspected case of bacterial pneumo-
nia and determining how long it should be given. These
include: (i) clinical presentation and severity; (ii) as-
sumed bacterial aetiology based upon the child’s age,
vaccination status, underlying co-morbidities and the
local pathogen antibiotic susceptibility profiles; and (iii)
cost, availability, tolerability, and ease of administration
(e.g. frequency and palatability) of the chosen agent that
may influence treatment adherence.
In clinical practice, the optimal duration of antibiotic
treatment depends upon whether the pneumonia is
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